Unravel Biosciences raised $4.1 million in convertible debt to advance its AI-driven drug discovery platform and pipeline of new and repurposed therapies for rare neurological disorders, including Rett syndrome and SYNGAP1-related disorders.
Investment Amount (In Millions): $4.10